Despite the emerging paradigm favoring continuous therapy, we found that in routine clinical care, myeloma patients at first relapse frequently discontinue treatment before progression, resulting in a therapy duration that is significantly shorter than the interval to the next therapy. We further describe the association between the length of second-line therapy and improved overall survival for patients with relapsed/refractory multiple myeloma. Background: In clinical trials, an extended therapy duration has been associated with better outcomes in patients with newly diagnosed multiple myeloma (NDMM). However, data on how the therapy duration affects the outcomes for patients with relapsed/refractory multiple myeloma (RRMM) are limited. We conducted a large, retrospective study in the United States to evaluate the effect of the duration of second-line therapy on overall survival. Patients and Methods: Adults with NDMM from January 2008 to June 2015 were followed up to identify their second-line therapy. The duration of therapy (DOT) and time to next therapy (TTNT), as a proxy for progression-free survival, were estimated using the Kaplan-Meier method. The relationship between the duration of second-line therapy and overall survival was evaluated with a logistic marginal structural model to mitigate the risk of treatment selection and survival bias. Results: A total of 628 NDMM patients developed a relapse after initial therapy. The median DOT for second-line therapy was 6.9 months (95% confidence interval [CI], 5.9-7.7 months), which was shorter than the corresponding TTNT (median, 15.1 months; 95% CI, 13.4-17.3 months). Each additional month of second-line therapy was associated with a reduced adjusted risk of death at 1 year (odds ratio, 0.78; 95% CI, 0.77-0.83; P < .001). Conclusion: In a large database capturing a heterogeneous patient population and varied treatment patterns reflecting routine clinical care, we found a clinical benefit for continued longer DOT at first relapse. Despite the emerging paradigm favoring continuous therapy, second-line progression-free survival (utilizing TTNT as the proxy) was more than twofold longer than the DOT. Understanding the barriers to extended DOT could help to improve the outcomes for RRMM patients.
Introduction
Multiple myeloma (MM) is the second-most common hematologic malignancy and primarily affects the elderly population. 1 Novel therapies have been associated with a significant improvement in overall survival (OS) for patients with MM 2, 3 ; however, relapse will be inevitable for most patients. Consensus has been increasing that prolonged therapy for patients with newly diagnosed MM (NDMM) correlates with improved patient outcomes. The phase III The Front-line Investigation of Revlimid and Dexamethasone versus Standard Thalidomide (FIRST) trial demonstrated that continuous frontline therapy with lenalidomide plus dexamethasone until disease progression leads to better progression-free survival (PFS) compared with fixed-duration therapy. 4 Also, post hoc analyses of trial data that examined the effect of fixed-duration versus continuous therapy or cumulative dose on patient outcomes demonstrated a beneficial effect from prolonged frontline therapy for patients with NDMM. 5, 6 Another retrospective analysis by Mateos et al 7 reported a significant benefit for PFS and time to progression (TTP), but not for OS, with less intensive prolonged therapy compared with a shorter, more intensive fixedduration treatment with a bortezomib, melphalan, and prednisone combination in NDMM.
With second-line therapy, evaluations of the effects of the duration of therapy (DOT) on outcomes have been limited to lenalidomide and dexamethasone therapy. These were based on subgroup analyses of large prospective trials in which treatment was given until progression or, alternatively, on small single-institution experiences. [8] [9] [10] [11] [12] In 1 study of 50 patients, those treated for > 3 years had a longer median TTP compared with those treated for 2 to 3 years, regardless of the response rate. 10 In another small retrospective study of 67 patients, OS and the overall response rate were significantly better for patients treated with lenalidomide and dexamethasone for > 12 months compared with patients who stopped treatment at < 12 months for reasons other than progression. 11 However, these studies varied in the extent to which they controlled for patient and disease factors and treatment exposure at baseline and over time-all aspects that can affect OS. Some analyses did not account for selection 8 and/ or survival 10, 12 bias. Others adjusted for baseline confounders but did not account for selection bias over time or survival bias. 11 Some included landmark analyses 8 or time-dependent multivariate Cox regression models. 9 However, with these traditional regression methods, including Cox regression models with time-varying covariates and landmark analyses, the possibility exists that the results could be biased in the presence of a time-dependent exposure (continuation of therapy) and time-varying confounders. [13] [14] [15] Larger, multi-institutional studies that encompass practice patterns outside of a clinical trial setting (ie, standard-of-care patients who tend to be older and have a greater comorbidity burden) and studies that apply robust statistical methods to account for selection and survival bias are necessary to further characterize and confirm the effects of second-line DOT on the outcomes of patients with RRMM. In the present retrospective cohort study, we examined the relationship of second-line DOT and outcomes in a large national cohort of 628 RRMM patients treated in routine care in the United States using the marginal structural model (MSM), including adjustment for patient, disease, and treatment factors.
Patients and Methods

Study Design and Data Source
The present study was a retrospective observational study of deidentified Humedica electronic medical record (EMR) data from January 1, 2007 to June 30, 2015. The EMR Humedica database is a large clinical database with a broad geographic representation from all 50 states and accounts for > 140,000 providers, 6500 clinics, and 600 hospitals in the United States. The source of Humedica data is primarily from large integrated delivery networks (IDNs) in the United States. Each IDN in Humedica is a comprehensive health care delivery system that offers patients a multitude of services across the clinical care spectrum, including acute inpatient and outpatient care. The Humedica EMR data set contains de-identified data for use in clinical research. The Chesapeake institutional review board approved the present study.
Study Cohort
Adult patients with NDMM who had received care within an IDN were identified for the present study. A diagnosis of MM was defined as ! 2 EMRs with an MM diagnosis code (International Classification of Diseases, 9th revision, Clinical Modification [ICD-9-CM] codes 203.00, 203.01, 203.02) ! 60 days but 1 year apart during the identification period from January 1, 2008 to June 30, 2015. The date of the first EMR with a diagnosis code for MM was used as the diagnosis date. Patients initiating first-line therapy were followed up after the MM diagnosis to identify subsequent lines of therapy ( Figure 1 ). Eligible patients were required to have continuous care for 12 months before the diagnosis date for NDMM (washout period) through the initiation of at least secondline therapy for RRMM. The start of second-line therapy was the index date for the analyses of outcomes. Patients with a history of frontline stem cell transplantation (SCT) before the initiation of second-line therapy were included. Those with a diagnosis of secondary cancers during the 12-month period before the diagnosis of MM or those who had undergone treatment outside the IDN (with the consequent risk of incomplete information) were excluded. Patients were further excluded if they (1) had evidence of amyloidosis or plasma-cell leukemia before the initiation of secondline therapy (index date); (2) had evidence of another primary cancer anytime during the study period; (3) did not undergo treatment with an MM-specific anticancer agent beyond the firstline therapy; (4) were only treated with a steroid (monotherapy with prednisone or short-term [< 90 days] dexamethasone); or (5) had undergone delayed SCT (defined as an SCT date > 300 days after the initiation of first-line therapy).
Study Variables
Therapy Lines and Second-line Therapy Duration. First-line therapy was designated as starting with the first claim for MM-directed systemic cancer therapy after the diagnosis date. The following MM-directed drug therapies were identified during the study period: bortezomib, lenalidomide, pomalidomide, thalidomide, carfilzomib, bendamustine, vorinostat, etoposide, panobinostat, cyclophosphamide, melphalan, vincristine, doxorubicin, liposomal doxorubicin, interferon-a, or steroids (dexamethasone, including monotherapy of ! 90 days' duration, and prednisone combined with other agents). 16 All agents received within 30 days after the day of the first infusion or fill date for orally administered drugs were grouped into a regimen. Continuation of first-line therapy, including transplantation consolidation and maintenance, was considered a part of first-line therapy. Second-line therapy was identified as any of the following: a switch in regimen; the addition of a new drug after first-line therapy; or repeat treatment after a treatment gap of > 3 months from the runout date of the last drug administered. The run-out date for infused and injected drugs was the latest date of administration plus 30 days; for drugs available through the pharmacy benefit, it was the fill date plus the days' supply minus 1. Third-line therapy was identified as a switch to, or addition of, a new drug after second-line therapy.
The duration of second-line therapy was calculated from the first infusion or fill date to the first occurrence of any of the following: the last infusion or fill date of all drugs in the second-line therapy regimen plus the run-out date, the start of third-line therapy, or death. Patients who were either receiving second-line therapy or had < 90 days of follow-up data available after the end of secondline therapy at the last observation were censored.
Other Variables. In addition to the DOT, other outcomes of interest included the time to next therapy (TTNT) as a surrogate measure for PFS and 1-year mortality. 17, 18 The TTNT was defined as the interval from the start of second-line therapy to the start of third-line therapy or death, whichever occurred first. Observations were censored at the lost to follow-up or the end of the study period (June 30, 2015). The patient, disease, and treatment factors that influence treatment selection and could have confounded the relationship between the duration of second-line therapy and OS were identified in the EMR data set. The baseline covariates before the start of second-line therapy included age, gender, race, diagnosis year, geographic region, and insurance type. In addition, the treatment-free interval (TFI; ie, the interval from the end of first-line therapy to the start of secondline therapy) was included as a proxy for the refractoriness to previous therapy (dichotomized at 60 vs. > 60 days). The interval from diagnosis to the start of second-line therapy was included to adjust for indolent versus aggressive relapse. 19 Cytogenetic information was extracted from free text in the EMRs, such as the progress notes and pathology reports, using natural language processing. High-risk cytogenetics were defined as the presence of del[17p], t [4;14] , or t [14;16] before the initiation of second-line therapy. 16 To account for disease burden, the presence of CRAB symptoms (hypercalcemia, renal insufficiency, anemia, bone lesions) at the initiation of secondline therapy was included as an indicator variable. The ICD-9-CM diagnosis and Current Procedural Terminology codes for skeletal fractures, cord compression, and surgery or radiation therapy were used as proxies for bone lesions. 20 Comorbidities of interest that could independently affect the treatment choice and DOT (renal insufficiency, cardiovascular disease [CVD], diabetes, peripheral neuropathy, and thromboembolic disease) were also identified during the 12-month baseline period before second-line therapy initiation. Renal insufficiency and hypercalcemia were identified by the ICD-9-CM diagnosis codes or a laboratory value indicating creatinine clearance at < 40 mL/min or serum creatinine of > 2 mg/dL and calcium level > 11.5 mg/dL (> 2.65 mmol/L), respectively. CVD was identified by ICD-9-CM codes for conditions that included acute myocardial infarction, coronary heart disease, and congestive heart failure. The presence of diabetes, CVD, peripheral neuropathy, and thromboembolic disease was identified if the relevant ICD-9-CM code occurred in ! 1 EMR. The Charlson comorbidity index was used to score the comorbidities within the baseline period. 21 The covariates for previous therapy exposure at the initiation of secondline therapy included the first-line therapy regimen type (immunomodulatory drug [IMID]-based, proteasome inhibitor [PI]-based, PIþIMID-based, other) and previous SCT. To account for the second-line regimen effect, we also controlled for the regimen type (IMID-based, PI-based, PIþIMID-based, other). Time-varying covariates that can confound the relationship between the continuation of therapy and 1-year mortality included proxies for toxicities (expressed as monthly indicators within each month of second-line therapy), including thrombocytopenia, anemia, neutropenia, febrile neutropenia, infection, CVD, renal insufficiency, and thromboembolic events, according to the presence of the corresponding ICD-9-CM diagnosis code (and laboratory results in the case of anemia, neutropenia, thrombocytopenia, and renal insufficiency). In addition, the initiation of a subsequent line of therapy was used as a surrogate for early disease progression within the first year from the start of second-line therapy. Thus, the initiation of a regimen (IMID-based, PI-based, PIþIMID-based, or other) for third-line therapy in the month the regimen began was defined as a time-varying covariate.
Statistical Analysis
All study variables are expressed as the mean AE standard deviation, percentage, or median. Univariate comparisons between groups were performed using the Student t test for continuous variables and the c 2 test for categorical variables. Kaplan-Meier analyses were performed to calculate the median DOT and TTNT from the start of second-line therapy.
An MSM was used to estimate the influence of second-line DOT on 1-year mortality (Supplemental Appendix in the online version). The MSM analysis was adjusted for patient, disease, and treatment factors that could confound the relationship between DOT and 1-year mortality (see the section "Other Variables" for the list of the baseline and time-varying covariates). A priori, we identified age and baseline comorbidities of interest at the start of second-line therapy (renal insufficiency, CVD, diabetes, peripheral neuropathy, and thromboembolic disease) to determine their influence on the relationship between second-line DOT and 1-year mortality. These analyses calculated an adjusted odds ratio (OR), which represents the odds of 1-year mortality for each additional month of continued therapy among patients who continuing with second-line therapy compared with the odds of death among those who discontinued second-line therapy. A sensitivity analysis to examine the durationesurvival relationship was also performed. To mirror the analytic approaches in previously reported studies that evaluated the effect of DOT on OS in NDMM, 2 landmark analyses were conducted using Cox proportional hazards models at 2 and 4 months after the initiation of second-line therapy. The Cox proportional hazards models included baseline covariates (the same as for the MSM analyses) to account for potential biases in patient and disease characteristics. 5, 7, 22 The outcome was mortality at 1 year after the start of second-line therapy.
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All P values were 2-sided, setting the threshold for significance at P < .05. Statistical analyses were performed using the SAS, version 9.2, and R, version 3.2.2, statistical software packages.
Results
A total of 628 patients who met the eligibility criteria were followed up from the diagnosis of MM to identify the second-line therapy. Approximately 50% of the cohort (302 of 628 patients) had a new diagnosis of MM in 2012 or later. The median follow-up duration from the start of second-line therapy was 13.0 months (interquartile range, 5.3-23.3 months). Overall, the study population had a median age of 70.0 years (range, 39-85 years) and a high comorbidity burden, with 69.0% of patients presenting with ! 1 of the comorbidities of interest at the initiation of second-line therapy. Overall, most patients received a doublet regimen for second-line therapy (79.1%; n ¼ 497). The most frequently used therapy in the second-line setting was an IMID-based regimen (44.1%; n ¼ 277), followed by a PI-based regimen (33.3%; n ¼ 209), with a few patients (8.9%; n ¼ 56) receiving a PI-and an IMID-based combination (Table 1) .
For all the 628 patients, the median duration of second-line therapy was 6.9 months (interquartile range, 2.7-15.3 months). A greater proportion of patients who continued with second-line therapy for > 15.3 months received IMID-based therapy without a PI (P ¼ .08, Table 1 ). A shorter duration of second-line therapy was associated with a greater number of comorbidities, as measured by the Charlson comorbidity index (P < .01), and a greater burden of the following baseline comorbidities: CVD, renal insufficiency, and anemia (P ¼ .04, P ¼ .01, and P < .01, respectively). Among the patients treated for > 6.9 months, a larger proportion had an MM diagnosis with known high cytogenetic risk (P ¼ .02). However, patients with a known high cytogenetic risk had the shortest TFI from the end of second-line therapy to the start of third-line therapy (mean, 1.8 months) compared with those with standard cytogenetic risk (mean, 4.0 months) or unknown cytogenetic risk (mean, 2.7 months). The remaining baseline characteristics, including previous treatment exposure, and TFI were well balanced across the DOT quartiles (Table 1) .
Overall, during the study period, of the 628 patients, 218 (34.7%) had initiated third-line therapy and 107 (17%) had died without initiating third-line therapy. The duration of second-line 
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therapy was consistently shorter than the corresponding TTNT from the start of second-line therapy. Based on the Kaplan-Meier estimates, the median TTNT from the start of second-line therapy was 15.1 months (95% confidence interval [CI], 13.4-17.3 months), and the corresponding median duration for second-line therapy was 6.9 months (95% CI, 5.9-7.7) among all patients who initiated treatment (Figure 2 ).
Effect of DOT on OS
Among the 628 RRMM patients who initiated second-line therapy, the median OS was 41.0 months (95% CI, 32.1-59.5 months). Given the extent of censoring beyond the second year of follow-up (> 50% patients censored) and the resultant small number of observed events, we evaluated 1-year OS as the outcome of interest.
An independent effect of duration in the second-line therapy on 1-year mortality was observed after accounting for biases in the likelihood of continuing second-line therapy and the independent likelihood of longer survival with a longer treatment duration ( Figure 3 ; Supplemental Table I-A in the online version). Each additional month of second-line therapy was associated with a reduced risk of death at 1 year (adjusted OR, 0.78; 95% CI, 0.77-0.83; P < .01). Extending the duration of second-line therapy from the median duration of 6.9 months to 11 months correlated with a 12.7% greater 1-year OS probability (Figure 4) . The sensitivity analyses of the DOT and 1-year OS relationship confirmed the main findings. In the 2-month landmark analysis, each additional month of second-line therapy was associated with a reduced risk of death (hazard ratio [HR], 0.67; 95% CI, 0.59-0.77) after adjusting for the baseline covariates. The 4-month landmark analysis demonstrated similarly consistent results (HR, 0.58; 95% CI, 0.45-0.75).
As expected, the 1-year mortality was significantly lower among the younger than among the older patients (OR for mortality, 0.37; 95% CI, 0.20-0.68). A trend toward greater 1-year mortality was observed among patients with ! 1 comorbidity of interest before the start of second-line therapy compared with those without any comorbidities (OR, 1.52; 95% CI, 0.85-2.70; Figure 3 , Supplemental Table I-A in the online version).
Discussion
From a large multicenter cohort of patients with RRMM treated in routine care in the United States, we found that a longer DOT was associated with an increased probability of 1-year OS from the initiation of second-line therapy. We further examined the relationship between DOT and TTNT. Our results indicated that the TTNT is more than twofold longer than the duration of second-line therapy, suggesting that in practice (unlike in clinical trials of relapsed MM), second-line treatment is frequently discontinued for reasons other than disease progression.
The results of the present observational analysis support and extend the findings from previously reported clinical trials. Using a landmark analysis at 12 months, continuous first-line therapy with a PI and/or an IMID for ! 2 years improved PFS and OS compared with fixed-duration therapy of 1 year. 5 Mateos et al 7 demonstrated
that a greater cumulative dose of bortezomib obtained by either a longer DOT and/or more intensive therapy among patients continuing to receive frontline triplet combination of bortezomib, melphalan, and prednisone (VMP) starting at 12 months and beyond was associated with significantly improved OS compared to a lower cumulative dose in NDMM patients. Another recently reported retrospective propensity score matched-pair analysis of patient-level data from 2 randomized phase III trials of NDMM transplantineligible patients treated with frontline VMP demonstrated that a prolonged, less-intensive VMP schedule was associated with a PFS and TTP benefit. 6 However, the OS did not differ compared with that with a more intensive fixed-duration approach. 6 That analysis did not report an adjustment for time-varying confounding or survival bias. A pooled analysis from 2 phase III randomized trials of a subset of 353 RRMM patients who had had a complete or very good partial response to lenalidomide plus dexamethasone at 12 months showed that with continued treatment, survival was improved compared with patients with a partial response. 8 A separate subgroup analysis of these same phase III trials using time-dependent Cox regression evaluated whether continued treatment until progression or death with lenalidomide plus dexamethasone in patients who had achieved at least a partial response affected OS outcomes compared with treatment discontinuation for reasons other than disease progression. 9 Among the 212 patients, each additional cycle of therapy reduced the HR for death by 7.9%. 9 Our findings, which demonstrated a positive, independent correlation between DOT and 1-year OS probability, are in line with the results of the aforementioned analyses of patients with MM. However, our study evaluated patients who were treated in routine clinical practice in the United States. We analyzed the duration of second-line therapy in an RRMM population receiving all novel and conventional therapies available during the study period. Furthermore, our study patients had a greater comorbidity burden and were older than those who were enrolled in those clinical trials. However, despite the heterogeneity in patient and disease characteristics and regimen types in second-line therapy, our findings from a large, national cohort have confirmed that an extended duration of second-line therapy was associated with longer OS. It is particularly important to highlight the improvement in OS, as opposed to PFS, which is often reported in phase III clinical trials of relapsed MM. The reasons for early discontinuation of second-line therapy are unknown but can vary from toxicity to practitioner and patient choice to other practical concerns. Unlike in the clinical trial environment, in which the International Myeloma Working Group criteria for progression are used, a clinically asymptomatic reappearance of a small monoclonal spike after previous complete remission, for example, might not result in either treatment discontinuation or initiation of a third-line regimen in a fragile realworld patient with comorbidities.
In prespecified stratified analyses based on age and the presence of baseline comorbidities of interest, we found that age had an 
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independent effect on the relationship between DOT and OS. Both younger (< 75 years) and older (! 75 years) patients benefited from longer second-line therapy; however, as expected, the 1-year OS was lower among the older group than among their younger counterparts for each month of therapy. Evidence is growing of the effect of age, not only on OS, but also on PFS, in MM. Dimopoulos et al 12 showed that the odds of experiencing long-term benefit from lenalidomide/dexamethasone therapy, defined as a PFS of ! 3 years, were approximately doubled for younger RRMM patients (age 65 years) compared with older patients. Zago et al 11 also showed that older age was negatively predictive of OS in RRMM patients. Finally, in a large retrospective analysis of NDMM patients, early mortality within 1 year of diagnosis was significantly lower among patients aged 70 years compared with those who were aged > 70 years. 3 Our results suggest that prolongation of therapy alone in older patients versus younger patients might not narrow the 1-year mortality gap between these groups, although for both age groups, increasing the DOT resulted in an increased probability of 1-year OS.
The study limitations included those inherent to any retrospective database study. It is possible that some comorbidities were not captured through the use of ICD-9-CM codes. Also, cytogenetic abnormalities were not uniformly available for most patients, either because cytogenetic testing was not performed in routine care or, if performed, the results were not available. The International Staging System stage was missing for most patients and was not incorporated as a covariate. Furthermore, patient compliance (adherence, persistence) with oral therapies and doses was not captured in the database and could conceivably affect the DOT or cumulative dose and, subsequently, the survival outcomes. Although the cumulative dose might be a better predictor of outcomes, the DOT is a commonly used surrogate for the cumulative dose. 5, 7, 9 In a separate analysis of another observational data set, we found a strong and significant correlation between the cumulative bortezomib dose and the duration of bortezomib-containing regimens (correlation coefficient, 0.77; P < .01) and between the cumulative lenalidomide dose and the duration of lenalidomide-containing regimens (correlation coefficient, 0.76; P < .01; data on file). A further limitation related to the evaluation of DOT is that although we used a robust method (MSM) to balance the treated and untreated groups at each successive month of follow-up to account for treatment selection biases over time and for survival bias, we could not directly incorporate the reasons for discontinuation (eg, prescriber or patient preference vs. toxicity vs. progression), because this information was not available in the Humedica data set. Discontinuation of second-line therapy due to censoring (eg, due to loss to follow-up) was balanced between the groups with the use of censoring weights. Similarly, symptoms that are typically associated with treatment-related toxicities and might lead to treatment discontinuation were incorporated into the probability of treatment weights at each month of follow-up during second-line therapy to balance the comparison groups. Finally, we used the regimen type in the third line of therapy as a time-varying covariate in the MSM analysis as a proxy for early disease progression within the first year of initiation of second-line therapy. To the extent that these events were captured in the EMR data, the groups were balanced for these measures in our MSM analysis.
Conclusion
The results from the present real-world analysis suggest that a longer duration of second-line therapy is significantly associated with improved 1-year OS for patients with RRMM. Despite the substantial heterogeneity in the patient and disease characteristics and treatment patterns, the clinical benefit of continued longer term therapy at relapse appears to be generalizable to patients receiving care in the routine care setting. Although younger patients (age < 75 years) appeared to benefit more than did their older counterparts at each successive month of continued second-line therapy, a positive durationesurvival relationship was also observed among the older patients. These results suggest a role for managing any barriers to keeping patients on therapy, irrespective of age, until disease progression. Importantly, our data suggest that the DOT is much shorter than the TTNT or PFS, indicating that patients might not be receiving treatment to progression in routine clinical care. With the accumulating evidence from clinical trials regarding the superiority of 3-drug combinations in delaying progression in RRMM compared with 2-drug combinations, increased use of triplet therapy could further contribute to the improved outcomes among patients treated in routine care.
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Clinical Practice Points
A longer duration of second-line therapy was significantly associated with improved 1-year OS for patients with RRMM. Early discontinuation of second-line therapy for RRMM was associated with inferior survival but is a frequent phenomenon in real-world MM practice. Understanding the barriers to extended DOT until progression, such as the ease and convenience of administration, costs, and tolerability, could be influential in improving the outcomes of patients with RRMM. Future inquiry into the effect of specific regimens and the influence of age on the durationeoutcome relationship in patients treated in the real-world setting is also needed.
